ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Evaluation of plasma p-tau217 for detecting amyloid pathology in a heterogeneous community-based cohort.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Diagnostic accuracy of plasma p-tau217 against amyloid PET: A meta-analysis of technical platform variability and ratio versus single marker comparisons.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Kidney Function and Blood and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Related Dementias: Systematic Review and Meta-Analysis.Journal of the American Society of Nephrology : JASN · 2026Pooled it
- From Cerebrospinal Fluid to Blood Draw: Plasma p-Tau217 as a Non-Invasive Biomarker for Alzheimer's Disease: A Fagan Nomogram-Based Meta-Analytic Study.Molecular neurobiology · 2026Pooled it
- Plasma Phosphorylated Tau 217 and Incident Mild Cognitive Impairment and Dementia in Older Women.JAMA network open · 2026Trial
- Cerebral oxygen extraction fraction as a physiological biomarker in vascular cognitive impairment: A study in older adults enriched for small vessel diseases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Plasma p-Tau217 and SPECT-Based eZIS in Mild Cognitive Impairment: Concordance Analysis with Validation in an Amyloid PET Sub-Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Discovery-Driven Plasma Proteomics Identifies a Multi-Protein Signature for Amyloid PET Positivity: A Machine Learning Analysis of the Bio-Hermes Cohort.International journal of molecular sciences · 2026Article
- Prevalence of high-risk plasma p-tau217 levels and 5-year transition of risk status in 70-year-olds.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- A clinically feasible framework to estimate tau pathology and clinical-biological discordance in the Alzheimer's disease spectrum.Alzheimer's research & therapy · 2026Article
- Evaluation of an in vivo biomarker of arteriolosclerosis (ARTS) and its associations with cognition and multimodal ATN(V) biomarkers in a cardiometabolic-risk enriched community cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Diagnostic and Prognostic Utility of Plasma p-tau217 for Alzheimer's Disease in Chinese Elderly: Insights From the SILCODE Study With a Derived Threshold.European journal of neurology · 2026Article
- Integration over reduction: multimodal PET and fluid biomarkers in Alzheimer's disease and beyond.Current opinion in neurology · 2026Review
- Baseline plasma p-tau217/Aβ42 as a sensitive marker for the severity of Alzheimer's disease continuum.Journal of translational medicine · 2026Article
- Association of neighborhood disadvantage with Alzheimer's disease pathology and the stability of blood-based biomarker performance.The journal of prevention of Alzheimer's disease · 2026Observational
- Evaluation of an in vivo biomarker of arteriolosclerosis (ARTS) and its associations with cognition and multimodal ATN(V) biomarkers in a cardiometabolic-risk enriched community cohort.medRxiv : the preprint server for health sciences · 2025Article
- Plasma p-tau217 and incident mild cognitive impairment and dementia in older women: 25-year prospective study in The Women's Health Initiative Memory Study.medRxiv : the preprint server for health sciences · 2025Article
- Evaluation of plasma p-tau217 for detecting amyloid pathology in a heterogeneous community-based cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Clinical validation of a plasma-based antibody-free LC-MS method for identifying CSF amyloid positivity in mild cognitive impairment.Frontiers in aging neuroscience · 2025Article
- Plasma p-tau217 and cognitive impairment: Evaluating biomarker equity across racial/ethnic groups in HABS-HD.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Plasma p-tau217 for Alzheimer's disease diagnosis: a memory clinic implementation approach.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
introductionStudies suggest excellent performance of plasma phosphorylated tau 217 (p-tau217) for detecting amyloid pathology, though studies in more representative populations are needed to validate previously determined cutpoints.
methodsPlasma p-tau217 utility for detecting amyloid pathology (Aβ) via amyloid positron emission tomography (PET) was assessed in a heterogeneous, community-based cohort in the Wake Forest Alzheimer's Disease Research Center (WFADRC). Participants with baseline plasma data (n = 598) were 21% Black; 313 cognitive unimpaired (CU), 214 mild cognitive impairment (MCI), and 64 dementia (DEM); 49% prediabetic, 44% hypertensive, 29% overweight/obese; and 64% had mild-to-moderate kidney disease. Gaussian-mixture models, logistic regression, and receiver operating curve analyses were performed.
resultsPlasma p-tau217 was associated with elevated Aβ deposition and accurately classified Aβ-positive participants (PET [n = 307]: area under the curve [AUC] = 94%-97%, cutpoint ≥ 0.338 pg/mL). DISCUSSION: Plasma p-tau217 is an accurate indicator of amyloid pathology in a heterogeneous cohort and is superior to other plasma biomarkers assessed. HIGHLIGHTS: The Wake Forest Alzheimer's Disease Research Center (WFADRC) is a heterogeneous cohort. p-tau217 levels were lower, on average, in cognitively unimpaired participants, females, and Black participants. Plasma p-tau217 classified amyloid positron emission tomography (PET)-positive individuals with high precision and performed better than p-tau181. Cutpoints and reference ranges of plasma p-tau217 were lower compared to recently published thresholds. Combining cutpoint approaches, a four-tier system captured cohort heterogeneity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.